Prevalence of Symptoms Meeting Criteria for Irritable Bowel Syndrome in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

OBJECTIVES:Symptoms compatible with irritable bowel syndrome (IBS) may co-exist in patients with inflammatory bowel disease (IBD), presenting a clinical dilemma for physicians. We conducted a systematic review and meta-analysis to examine this issue.METHODS:MEDLINE, EMBASE, and EMBASE Classic were searched (through February 2012) to identify cross-sectional surveys or case-control studies reporting the prevalence of symptoms meeting diagnostic criteria for IBS in ≥50 unselected adult IBD patients. The number of individuals with symptoms meeting criteria for IBS was extracted for each study, and pooled prevalence and odds ratios (ORs), with 95% confidence intervals (CIs), were calculated.RESULTS:The search identified 3,045 articles. Thirteen studies, containing 1,703 patients, were eligible. The pooled prevalence for IBS in all IBD patients was 39% (95% CI 30–48%), with an OR compared with controls of 4.89 (95% CI 3.43–6.98). In IBD patients in remission, the OR was 4.39 (95% CI 2.24–8.61). For IBD patients with active disease, the pooled prevalence of IBS was 44%, compared with 35% in those felt to be in remission (OR 3.89; 95% CI 2.71–5.59). The prevalence in patients with Crohn's disease (CD) was higher than in those with ulcerative colitis (UC; 46 vs. 36%, OR 1.62; 95% CI 1.21–2.18).CONCLUSIONS:Symptoms compatible with IBS were significantly higher in patients with IBD compared with non-IBD controls, even among those felt to be in remission. IBS-type symptoms were also significantly more common in CD than in UC patients, and in those with active disease. Management strategies for IBD patients with symptoms suggestive of IBS are required.

[1]  A. Ford,et al.  Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  T. Hibi,et al.  Randomized , Double-Blind , Sham-Controlled Study of ranulocyte / Monocyte Apheresis for Active Ulcerative Colitis , 2008 .

[3]  P. Moayyedi,et al.  Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  C. Büning,et al.  Impact of pain on health-related quality of life in patients with inflammatory bowel disease. , 2010, World journal of gastroenterology.

[5]  F. Shanahan,et al.  Irritable Bowel Syndrome – Type Symptoms in Patients With Infl ammatory Bowel Disease : A Real Association or Refl ection of Occult Infl ammation ? , 2010 .

[6]  William J. Tremaine,et al.  Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000 , 2007, Inflammatory bowel diseases.

[7]  Ken Kleinman,et al.  The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  P. Ducrotte,et al.  Impact of functional bowel symptoms on quality of life and fatigue in quiescent Crohn disease and irritable bowel syndrome , 2010, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[9]  F. Shanahan,et al.  Irritable Bowel Syndrome–Type Symptoms in Patients With Inflammatory Bowel Disease: A Real Association or Reflection of Occult Inflammation? , 2010, The American Journal of Gastroenterology.

[10]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[11]  M. Camilleri,et al.  Fecal Lactoferrin Is a Sensitive and Specific Marker in Identifying Intestinal Inflammation , 2003, American Journal of Gastroenterology.

[12]  K W Heaton,et al.  Functional bowel disorders and functional abdominal pain , 1999, Gut.

[13]  P. V. van Rheenen,et al.  Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis , 2010, BMJ : British Medical Journal.

[14]  P. Moayyedi,et al.  Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis , 2008, Gut.

[15]  RichardF. Harvey,et al.  ORGANIC AND FUNCTIONAL DISORDERS IN 2000 GASTROENTEROLOGY OUTPATIENTS , 1983, The Lancet.

[16]  D. Drossman,et al.  Editorial: Inflammatory Bowel Disease, Irritable Bowel Syndrome, or What?: A Challenge to the Functional–Organic Dichotomy , 2010, The American Journal of Gastroenterology.

[17]  G PLACITELLI,et al.  [Ulcerative colitis]. , 1958, La Riforma medica.

[18]  K. Heaton,et al.  Towards positive diagnosis of the irritable bowel. , 1978, British medical journal.

[19]  G. Barbara,et al.  Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. , 2007, Gastroenterology.

[20]  P. Moayyedi,et al.  Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis , 2008, BMJ : British Medical Journal.

[21]  P. Whorwell,et al.  Symptoms of irritable bowel syndrome in ulcerative colitis in remission , 1983, Gut.

[22]  S. Targan,et al.  Identification of a prodromal period in Crohn's disease but not ulcerative colitis , 2000, American Journal of Gastroenterology.

[23]  D. Santini,et al.  Mucosal Immune Activation in Irritable Bowel Syndrome: Gender-Dependence and Association With Digestive Symptoms , 2009, The American Journal of Gastroenterology.

[24]  D. Forman,et al.  Irritable Bowel Syndrome: A 10-Yr Natural History of Symptoms and Factors That Influence Consultation Behavior , 2008, The American Journal of Gastroenterology.

[25]  P. Moayyedi,et al.  Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. , 2009, Archives of internal medicine.

[26]  A. Forbes,et al.  Functional symptoms in inflammatory bowel disease and their potential influence in misclassification of clinical status , 2005, Alimentary pharmacology & therapeutics.

[27]  A. Poullis,et al.  A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders , 2002, European journal of gastroenterology & hepatology.

[28]  D. Sanders,et al.  Reflux and irritable bowel syndrome are negative predictors of quality of life in coeliac disease and inflammatory bowel disease , 2011, European journal of gastroenterology & hepatology.

[29]  D. Drossman,et al.  Identification of sub-groups of functional gastrointestinal disorders , 1990 .

[30]  E. Björnsson,et al.  Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors , 2002, American Journal of Gastroenterology.

[31]  Roger Jones,et al.  Irritable bowel syndrome in the general population. , 1992, BMJ.

[32]  D. Santini,et al.  Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. , 2004, Gastroenterology.

[33]  W. Chey,et al.  An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome , 2008, The American Journal of Gastroenterology.

[34]  N. Talley,et al.  Identifying dyspepsia and irritable bowel syndrome: the value of pain or discomfort, and bowel habit descriptors. , 2000, Scandinavian journal of gastroenterology.

[35]  J. Ioannidis,et al.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials , 2011, BMJ : British Medical Journal.

[36]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[37]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[38]  F. Farrokhyar,et al.  Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: Prevalence and impact on health , 2006, Inflammatory bowel diseases.

[39]  Clifford Goodman,et al.  The burden of selected digestive diseases in the United States. , 2002, Gastroenterology.

[40]  Peter Henningsen,et al.  Medically Unexplained Physical Symptoms, Anxiety, and Depression: A Meta‐Analytic Review , 2003, Psychosomatic medicine.

[41]  A. Zinsmeister,et al.  Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival , 2000, Gut.

[42]  R. Malekzadeh,et al.  Ulcerative colitis and irritable bowel syndrome: relationships with quality of life , 2008, European journal of gastroenterology & hepatology.

[43]  Wangxue Chen,et al.  Activation of the mucosal immune system in irritable bowel syndrome. , 2002, Gastroenterology.

[44]  R. A’Hern,et al.  Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea‐predominant irritable bowel syndrome , 2009, Alimentary pharmacology & therapeutics.

[45]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[46]  J. Andrews,et al.  The effect of functional gastrointestinal disorders on psychological comorbidity and quality of life in patients with inflammatory bowel disease , 2008, Alimentary pharmacology & therapeutics.

[47]  D. Drossman,et al.  The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[48]  D. Sanders,et al.  Prodromal Irritable Bowel Syndrome May Be Responsible for Delays in Diagnosis in Patients Presenting with Unrecognized Crohn’s Disease and Celiac Disease, but Not Ulcerative Colitis , 2011, Digestive Diseases and Sciences.

[49]  P. Moayyedi,et al.  The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review , 2008, Gut.

[50]  H. Verspaget,et al.  Symptoms in patients with ulcerative colitis in remission are associated with visceral hypersensitivity and mast cell activity , 2011, Scandinavian journal of gastroenterology.

[51]  B. Oldenburg,et al.  IBS-Like Symptoms in Patients with Inflammatory Bowel Disease in Remission; Relationships with Quality of Life and Coping Behavior , 2004, Digestive Diseases and Sciences.

[52]  R Jones,et al.  Guidelines on the irritable bowel syndrome: mechanisms and practical management , 2007, Gut.

[53]  P. Openshaw,et al.  Towards positive diagnosis of the irritable bowel. , 1978, British medical journal.

[54]  A. Zinsmeister,et al.  Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. , 1998, Gastroenterology.

[55]  J. Andrews,et al.  Functional gastrointestinal disorders in inflammatory bowel disease: Impact on quality of life and psychological status , 2011, Journal of gastroenterology and hepatology.